Lunaphore and Abcam Announce Agreement for Primary Antibody Validation for Use on COMET™, Combining Power of Trusted Antibody Provider With Superior Multiplex Capabilities
6.4.2023 18:04:00 EEST | Business Wire | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and abcam (NASDAQ: ABCM), a global life science company working together with researchers to advance science and enable faster breakthroughs, today announced an agreement to co-market abcam primary antibodies specifically validated for use on Lunaphore’s COMET™ platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005514/en/
The agreement will enable researchers to use abcam’s antibodies without conjugation directly on the COMET™ platform, with unparalleled scalability and reproducibility. By using validated primary antibodies together with the capabilities of COMET™, researchers can accelerate assay development processes and achieve reliable results. The partnership also aims to address the reproducibility crisis in life sciences by providing trusted tools for multiplex immunofluorescence analysis.
Lunaphore recently expanded its offerings to become the first universal, end-to-end solution for spatial biology research. Lunaphore’s COMET™ is the only high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. It has a wide range of research applications across multiple disciplines and drug development stages, provides walk-away automation, and allows for the generation of highly robust and reproducible hyperplex data with full tissue preservation that answers the growing needs of translational research.
“This collaboration underscores the importance we place on using antibodies from trusted and proven vendors like abcam. We understand how important it is to the research community to use antibodies that they already know and rely on and be able to directly transfer and use them for multiplexing,” said Déborah Heintze, Chief Marketing Officer at Lunaphore. “We are very proud to see how customers can already optimize and run new panels in days. Proposing validated abcam antibodies on COMET will help streamline and scale the researchers’ multiplexing capabilities even more.”
“We’re excited to be partnering with Lunaphore to offer the life science community a library of primary antibodies validated for use with Lunaphore’s automated platform for hyperplex immunofluorescence analysis,” said Courtney Nicholson, Vice President Business Development at abcam. “Spatial biology is truly revolutionizing our understanding of human health and disease, and we are pleased to be working together with Lunaphore to support researchers with the tools they need to further advance this promising new field.”
Lunaphore and abcam will present novel data together in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, highlighting shared research:
Automated multiplex immunofluorescence enables single cell analysis of tumor stroma
Poster #: 4616, Section 4
Date and time: April 18, 1:30 pm – 5:00 pm EST
Speaker: Dr. François Rivest, Application Development Team Leader, Lunaphore
About COMET™
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. Orders of the new COMET™ version can be placed and will be available for shipment in the upcoming months. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
About abcam
At abcam, we believe that the scientific community goes further, faster, when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That’s why we’re constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications.
We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.
To find out more, visit us at www.abcam.com and corporate.abcam.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005514/en/
Contact information
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
Abcam Corporate Communications
Email : external.comms@abcam.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexGen’s HybridOS Energy Management System Receives ISO 9001:2015 Certification, Strengthening Its Platform to Serve International Markets29.7.2026 15:00:00 EEST | Press release
FlexGen Power Systems, LLC. (“FlexGen”), a leading battery energy storage system and energy management software provider, today announced that its HybridOS energy management platform is ISO 9001:2015 certified. ISO 9001:2015 is an internationally recognized standard for quality management, meaning the systems and processes behind HybridOS, from design, development, deployment, and remote software support, have been accredited by the certification body. “Battery storage is critical infrastructure for keeping the lights on, but it can only do its job if grid operators can trust it to perform when it’s needed,” said Mike Wallace, Managing Director of Europe for FlexGen. “Security, safety, and quality must be built into every layer of battery storage technology to ensure it can be relied on to power industry, mission-critical systems, and residences. High availability, high performance, and high security standards are all a must for battery storage assets needed across the globe.” This cer
Copeland Enters into Exclusive Negotiations to Acquire Dickson, Advancing Cold Chain Leadership29.7.2026 15:00:00 EEST | Press release
Copeland, a global leader in compression technologies and controls solutions, today announced its entry into exclusive negotiations towards the purchase of Dickson, a portfolio company of May River Capital and provider of environmental monitoring and cloud-native software solutions for regulated life sciences and healthcare applications. The proposed acquisition will strengthen Copeland’s strategy of enabling an efficient and effective cold chain, building on its existing stationary and in-transit monitoring capabilities to deliver an end-to-end solution that helps healthcare, pharmaceutical and life sciences customers safeguard product integrity, maintain compliance and reduce operational risk. Quality assurance and environmental monitoring represents a large and secularly growing market opportunity, driven by increasing regulatory requirements, the expansion of biologics and cell and gene therapies, and rising demand for supply chain transparency. Dickson's cloud-native monitoring pl
Wind Point Partners Announces Final Close of Oversubscribed Fund XI at $3.2 Billion29.7.2026 15:00:00 EEST | Press release
Wind Point Partners (“Wind Point”), a leading Chicago-based private equity firm, today announced the successful closing of its latest fund, Wind Point Partners XI (“Fund XI” or the “Fund”). Fund XI was oversubscribed and exceeded the hard cap, with total commitments of $3.2 billion. This amount includes significant commitments by the General Partner and members of the firm’s Executive Advisor Partner (“EAP”) program, providing strong alignment across all investors in the Fund. Fund XI represents Wind Point’s largest fund to date and its most global and diverse investor base in the firm’s 42-year history. Fund XI received commitments from more than 65 global institutions spanning 17 countries, including pension funds, insurance companies, asset managers, family offices and foundations. Propelled by significant repeat support from existing investors, the efficient fundraise process was completed in under nine months. Founded in 1984, Wind Point has a long history of partnering with top-c
Workiva Launches Specialized AI Agents and Intelligence Layer to Advance High-Stakes Reporting29.7.2026 15:00:00 EEST | Press release
Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, today announced three purpose-built AI agents and Workiva Knowledge, a persistent intelligence layer grounded in an organization's data, instructions, and content. The agents will help customers in advanced solution tiers accelerate reporting and compliance outcomes with the control and traceability of the Workiva platform. Together, these capabilities offer enterprise teams governed AI at the speed and scale their organizations require. "Finance, sustainability, risk, and compliance teams are moving from execution to orchestration as AI agents take on more of the work, and we're building the platform that makes that transformation possible," said Deepak Bharadwaj, Chief Product Officer of Workiva. "As we evolve the Workiva platform, we're staying true to what our customers have always counted on us to deliver: accuracy, transparency, and solutions shaped by the reality and complexity
Xpress Genomics Joins Parse Biosciences’ Certified Service Provider Network29.7.2026 15:00:00 EEST | Press release
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing, and a QIAGEN company, today announced that Xpress Genomics has joined its Certified Service Provider (CSP) program, becoming the first in the Nordic region. The Stockholm-based company will offer Parse's Evercode single cell sequencing portfolio to researchers through its existing sequencing service pipeline. Originating out of the Karolinska Institutet in 2022, Xpress Genomics has built automated, in-house workflows for NGS projects. Joining the CSP program adds Evercode to the company's service offerings, giving its customers direct access to Parse's split-pool single cell technology. "Our customers expect fast, high-quality results," said Christoph Ziegenhain, CEO at Xpress Genomics. "Offering Evercode through our CSP membership gives them a strong option for single cell projects, backed by the same turnaround and quality standards our lab runs on." "Adding Xpress Genomics to our CSP program m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom